Rabbit Polyclonal UBXN11 Antibody

+ +

•  

   
     Western blot analysis of SAP49 expression in HEK293T, Jurkat whole cell lysates.    

•  

   
     Immunofluorescent analysis of UBXN11 staining in K562 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).    

•  

   
     Immunohistochemical analysis of UBXN11 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.    

The UBXN11 antibody targets the ubiquitin regulatory X (UBX) domain-containing protein 11. a member of the UBX protein family involved in ubiquitin-dependent cellular processes. UBXN11. also known as UBXD9 or SOC, contains a UBX domain that facilitates interactions with p97/VCP (valosin-containing protein), a key ATPase regulating proteasomal degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. UBXN11 is thought to act as a cofactor modulating p97’s activity in these pathways, though its precise mechanisms remain under investigation.

Functionally, UBXN11 has been implicated in diverse processes, including cell cycle regulation, DNA damage response, and apoptosis. Studies suggest it may compete with other UBX proteins to regulate p97’s substrate processing or serve as an adaptor linking p97 to specific ubiquitinated targets. Its role in ERAD highlights potential connections to protein quality control and diseases like neurodegeneration or cancer. However, conflicting reports on its pro- or anti-apoptotic effects underscore the need for further research to clarify its context-dependent functions.

UBXN11 antibodies are widely used in Western blotting, immunoprecipitation, and immunofluorescence to study its expression, localization, and interactions. Commercial antibodies are typically raised in rabbits or mice against specific epitopes, with validation via knockout cell lines or siRNA knockdown. These tools have advanced research into UBXN11’s regulatory roles in ubiquitination pathways and its potential as a therapeutic target, though challenges in specificity and functional redundancy within the UBX family persist.